XCR1 and neoplasm: Indeed, a similar scenario has been shown previously for a mutated type I interferon with a decreased receptor affinity.[58] The injection of the mutated cytokine conjugated to an Nb targeting Clec9A, expressed by XCR1+ cDC1s, in tumor‐bearing mice drastically decreased tumor growth, indicating that the activity of the mutated cytokine is selectively restored for cell populations expressing Clec9A, while minimizing systemic toxicity.